New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

With the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1–3, platelet-derived growth factor, and c-kit, six agents are now available for use in the management of metastatic renal cell carcinoma (RCC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Cowey, C Lance, Sonpavde, Guru, Hutson, Thomas E
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962303/
https://www.ncbi.nlm.nih.gov/pubmed/21049083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962303/
https://www.ncbi.nlm.nih.gov/pubmed/21049083

Ejemplares similares